Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02610283 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Efficacy and Safety of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery
A Phase 2 study, sponsored by Quark Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 341
- Enrollment target
NCT02610283: Completed Phase 2 study, sponsored by Quark Pharmaceuticals.
NCT02610283 is a Phase 2 study that has completed, run by Quark Pharmaceuticals. The registered enrollment target is 341 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (156% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02610283, a Phase 2 study, has completed, sponsored by Quark Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 341 participants
- Enrollment target
Study Summary
This trial is designed to evaluate QPI-1002 versus placebo for the prevention of AKI in subjects who are at high risk for AKI following cardiac surgery. Half of the participants will receive QPI-1002 while the other half will receive placebo.
Interventions
- DRUG Placebo
- DRUG QPI-1002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 341 participants |
| Start Date | 2015-12 |
| Est. Completion | 2018-04 |
| Phase | Phase 2 |
What the finished NCT02610283 record still lists
NCT02610283 is an interventional study that assigns participants to a tested intervention. The registered 341 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (156% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02610283 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02610283 about?
NCT02610283 is a clinical study titled "A Study to Evaluate Efficacy and Safety of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery". This trial is designed to evaluate QPI-1002 versus placebo for the prevention of AKI in subjects who are at high risk for AKI following cardiac surgery. Half of the participants will receive QPI-1002 while the other half will receive placebo.
What is the current status of trial NCT02610283?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 341 participants. The study started on 2015-12. Estimated completion is 2018-04.
What interventions are being tested in trial NCT02610283?
The interventions under investigation include: Placebo (DRUG), QPI-1002 (DRUG).
Who is sponsoring clinical trial NCT02610283?
This trial is sponsored by Quark Pharmaceuticals, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02610283's enrollment target sits among peer trials
341 137th of 2000 higher than 1,864 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06852170 · 341 participants · NA
Data2Action Oregon Project: Supporting Data-driven Decision-Making for Substance Use Services, Policy, and Overdose Prevention
- NCT05283850 · 342 participants · Phase 2
Surviving PEA in Roanoke (SPEAR) Study
- NCT05714085 · 342 participants · Phase 2
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
- NCT06188702 · 342 participants · Phase 1
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia